FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983534004> ?p ?o ?g. }

• W1983534004 endingPage "453" @default.
• W1983534004 startingPage "438" @default.
• W1983534004 abstract "The purpose of this clinical study was to determine the efficacy, tolerability, and impact on quality of life of domperidone--a specific peripherally acting dopamine antagonist--in the management of symptoms of gastroparesis, a common and potentially debilitating condition in patients with diabetes mellitus. In the first phase of this multicenter, two-phase withdrawal study, 287 diabetic patients with symptoms of gastroparesis of at least 6 months' duration received domperidone 20 mg QID in a single-masked fashion for 4 weeks. Efficacy was evaluated using a four-point rating scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) for each of the following symptoms: nausea, abdominal distention/bloating, early satiety, vomiting, and abdominal pain. At the end of the first phase, patients with sufficient improvement in their total symptom score (a score < or = 6 and a decrease in score of > or = 5 units from the baseline [selection] visit) were eligible for the 4-week, randomized, placebo-controlled, double-masked withdrawal phase of the study. The impact of domperidone on quality of life was determined using the Medical Outcomes Study Short Form-36 (SF-36). Of 269 patients with data from the single-masked phase, 208 (77%) qualified for entry into the double-masked phase based on a statistically significant improvement in total symptom score, from a mean score of 10.32 at baseline (initial visit) to 3.79 after 4 weeks of single-masked domperidone therapy. During the double-masked phase, patients in the placebo group had significantly greater deterioration in total symptom scores compared with patients in the domperidone group (mean changes of 1.84 and 0.85, respectively). Similar significant differences in favor of domperidone were seen in the secondary efficacy variables (i.e., patients' diary scores and global assessments of symptoms). The tolerability profile of domperidone was similar to that of placebo. Patients who responded to domperidone experienced significant improvements in quality of life, as indicated by the SF-36 physical and mental component summary scores. During the double-masked phase, patients who were randomized to placebo experienced a significant deterioration in the physical component summary score compared with patients in the domperidone group. The results of this study suggest that domperidone 20 mg QID provides significant improvement in the upper gastrointestinal symptoms of diabetic gastroparesis and is well tolerated in patients with this condition." @default.
• W1983534004 created "2016-06-24" @default.
• W1983534004 creator A5005028574 @default.
• W1983534004 creator A5033749127 @default.
• W1983534004 creator A5038102817 @default.
• W1983534004 creator A5043444899 @default.
• W1983534004 creator A5053396290 @default.
• W1983534004 creator A5054183066 @default.
• W1983534004 creator A5058152911 @default.
• W1983534004 creator A5070720005 @default.
• W1983534004 creator A5088952586 @default.
• W1983534004 creator A5089234877 @default.
• W1983534004 date "1998-05-01" @default.
• W1983534004 modified "2023-10-01" @default.
• W1983534004 title "Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial" @default.
• W1983534004 cites W1965633911 @default.
• W1983534004 cites W1980628545 @default.
• W1983534004 cites W1991206266 @default.
• W1983534004 cites W2015229217 @default.
• W1983534004 cites W2020961258 @default.
• W1983534004 cites W2030926336 @default.
• W1983534004 cites W2034970442 @default.
• W1983534004 cites W2036338907 @default.
• W1983534004 cites W2037244782 @default.
• W1983534004 cites W2048056589 @default.
• W1983534004 cites W2053151511 @default.
• W1983534004 cites W2064997097 @default.
• W1983534004 cites W2071006966 @default.
• W1983534004 cites W2085521848 @default.
• W1983534004 cites W2099604717 @default.
• W1983534004 cites W2112696273 @default.
• W1983534004 cites W2151883852 @default.
• W1983534004 cites W2312845168 @default.
• W1983534004 cites W2768521010 @default.
• W1983534004 cites W4292806894 @default.
• W1983534004 cites W4361866704 @default.
• W1983534004 doi "https://doi.org/10.1016/s0149-2918(98)80054-4" @default.
• W1983534004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9663360" @default.
• W1983534004 hasPublicationYear "1998" @default.
• W1983534004 type Work @default.
• W1983534004 sameAs 1983534004 @default.
• W1983534004 citedByCount "131" @default.
• W1983534004 countsByYear W19835340042012 @default.
• W1983534004 countsByYear W19835340042013 @default.
• W1983534004 countsByYear W19835340042014 @default.
• W1983534004 countsByYear W19835340042015 @default.
• W1983534004 countsByYear W19835340042016 @default.
• W1983534004 countsByYear W19835340042017 @default.
• W1983534004 countsByYear W19835340042018 @default.
• W1983534004 countsByYear W19835340042019 @default.
• W1983534004 countsByYear W19835340042020 @default.
• W1983534004 countsByYear W19835340042021 @default.
• W1983534004 countsByYear W19835340042022 @default.
• W1983534004 countsByYear W19835340042023 @default.
• W1983534004 crossrefType "journal-article" @default.
• W1983534004 hasAuthorship W1983534004A5005028574 @default.
• W1983534004 hasAuthorship W1983534004A5033749127 @default.
• W1983534004 hasAuthorship W1983534004A5038102817 @default.
• W1983534004 hasAuthorship W1983534004A5043444899 @default.
• W1983534004 hasAuthorship W1983534004A5053396290 @default.
• W1983534004 hasAuthorship W1983534004A5054183066 @default.
• W1983534004 hasAuthorship W1983534004A5058152911 @default.
• W1983534004 hasAuthorship W1983534004A5070720005 @default.
• W1983534004 hasAuthorship W1983534004A5088952586 @default.
• W1983534004 hasAuthorship W1983534004A5089234877 @default.
• W1983534004 hasConcept C126322002 @default.
• W1983534004 hasConcept C142724271 @default.
• W1983534004 hasConcept C159110408 @default.
• W1983534004 hasConcept C197934379 @default.
• W1983534004 hasConcept C204787440 @default.
• W1983534004 hasConcept C27081682 @default.
• W1983534004 hasConcept C2775995038 @default.
• W1983534004 hasConcept C2776956441 @default.
• W1983534004 hasConcept C2778375690 @default.
• W1983534004 hasConcept C2778769438 @default.
• W1983534004 hasConcept C2779422922 @default.
• W1983534004 hasConcept C2779951463 @default.
• W1983534004 hasConcept C2780580376 @default.
• W1983534004 hasConcept C2780852908 @default.
• W1983534004 hasConcept C2780955771 @default.
• W1983534004 hasConcept C3020479747 @default.
• W1983534004 hasConcept C42219234 @default.
• W1983534004 hasConcept C513476851 @default.
• W1983534004 hasConcept C71924100 @default.
• W1983534004 hasConceptScore W1983534004C126322002 @default.
• W1983534004 hasConceptScore W1983534004C142724271 @default.
• W1983534004 hasConceptScore W1983534004C159110408 @default.
• W1983534004 hasConceptScore W1983534004C197934379 @default.
• W1983534004 hasConceptScore W1983534004C204787440 @default.
• W1983534004 hasConceptScore W1983534004C27081682 @default.
• W1983534004 hasConceptScore W1983534004C2775995038 @default.
• W1983534004 hasConceptScore W1983534004C2776956441 @default.
• W1983534004 hasConceptScore W1983534004C2778375690 @default.
• W1983534004 hasConceptScore W1983534004C2778769438 @default.
• W1983534004 hasConceptScore W1983534004C2779422922 @default.
• W1983534004 hasConceptScore W1983534004C2779951463 @default.
• W1983534004 hasConceptScore W1983534004C2780580376 @default.
• W1983534004 hasConceptScore W1983534004C2780852908 @default.

• next